Table 1 Baseline and week-12 characteristics in patients
| Â | All patients | Baseline | Â | Â | Week 12 | Â |
|---|---|---|---|---|---|---|
| Â | Â | Responder (week 12) | Nonresponder (week 12) | All patients | Responder | Nonresponder |
Number | 20 | 10 | 10 | 20 | 10 | 10 |
TJC of 28 joints | 8.25 (±7.2) | 9.20 (±8.7) | 7.30 (±5.8) | 3.16 (±3.3) | 2.20 (±3,2) | 4.22 (±3.3) |
SJC of 28 joints | 5.45 (±3.7) | 5.90 (±3.1) | 5.00 (±4.3) | 1.79 (±2.7) | 0.70 (±1.9) | 3.00 (±3.1) |
VAS general disease activity | 47.8 (±20.4) | 52.6 (±19.3) | 42.9 (±21.4) | 27.6 (±18.6) | 21.6 (±16.9) | 34.2 (±19.1) |
ESR, mm/h | 23.7 (±13.6) | 19.1 (±10.5) | 28.3 (±15.3) | 17.8 (±14.2) | 11.1 (±7.3) | 25.1 (±16.7) |
C reactive protein, mg/dl | 7.22 (±6.5) | 6.65 (±4.9) | 7.79 (±8.0) | 5.40 (±8.9) | 2.71 (±3.1) | 8.3 (±12.3) |
DAS28 | 4.76 (±1.2) | 4.82 (±1.2) | 4.7 (±1.2) | 3.33 (±1.4) | 2.50 (±1.1) | 4.17 (±1.2) |
Age, years | 53.65 (±9.4) | 53.5 (±10.7) | 53.8 (±8.5) | - | - | - |
Sex, female, % | 70 | 60 | 80 | - | - | - |
Disease duration, years | 4.35 | 4.3 | 4.4 | - | - | - |
Rheumatoid factor, +/-, % | 65/35 | 70/30 | 60/40 | - | - | - |
Anti CCP, +/-, % | 80/20 | 80/20 | 80/20 | - | - | Â |